Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Asco Gu abstract released
View:
Comment by DJDawg on Feb 13, 2023 6:52pm
As expected, based on the deadline for abstract submission back in Oct. The abstract reports. Assessment 90 Day 180 Day 270 Day 360 Day 450 Day CR 50% 47% 41% 35% 21% IR 16% 26% 22% 12% 13% Total Response 66%  ...more  
Comment by Eoganacht on Feb 14, 2023 12:01pm
It's good to remember that 8 of the 24 evaluable patients were undertreated and did not receive an optimized treatment. So 33% of the sample of  24 patients had no chance of a CR. 21% CR at 450 days in no way reflects the actual efficacy of the treatment. As mentioned by DJDawg, in the more recent data release from Nov. 29 the CR rate at 450 days was 28%. If just 2 of the 8 completely ...more  
Comment by fredgoodwinson on Feb 14, 2023 12:20pm
Yes Eog - really can`t see what`s holding it back. BTW is the vaccine being trialled in humans yet?  Thanks.
Comment by Eoganacht on Feb 14, 2023 12:52pm
Hi Fred - it looks like it will be 2024 before human testing begins. 2023 will be devoted to testing the vaccine in animals. This is from the latest MD&A: In July 2022, Theralase® executed a Testing and Technical Services Agreement (“TTSA”) with the National Research Council of Canada (“NRC”) to produce inactivated SARS-CoV-2 virus using Theralase®’s patented PDC and proprietary ...more  
Comment by ScienceFirst on Feb 14, 2023 12:24pm
Eoganacht ... I agree.  The more patients we add to our sample, the higher will be our efficacy %s.
Comment by hilles on Feb 13, 2023 6:54pm
Look very good to me. Imagine if we treat the patient every 180 days....!
Comment by ScienceFirst on Feb 13, 2023 8:46pm
Apart data, which is phenomenal when compared to competition and that confirms my previous posts on potential upcoming efficacy %s around 65%+ @450-days as we add more and more optimized patients and will secure a FDA approval in due time, there are these others things that are very interesting in this poster: 1) Excellent Safety profile: None of the SAEs were deemed to be directly related to ...more  
Comment by ScienceFirst on Feb 13, 2023 8:52pm
TR% of 65%+ will allow patients to avoid/delay any cystectomy.  The FDA cannot disregard this.  Expects Breakthrough Therapy designation and/or Accelerated Approval with complete FDA approval in due time.
Comment by FGPstock on Feb 13, 2023 10:25pm
tuesday is typically news day, lets hope they put some more positive data out before the presentation...
Comment by Oilminerdeluxe on Feb 14, 2023 2:49am
A new ATH would be nice to see some day. Sigh, 38 cents. Maybe the next update or two will do the trick. That usually does not happen. But here's to hoping!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250